ReviewEuropean urology focus2024
Mechanism of Nephrolithiasis: Does the Microbiome Play a Role?
Review in European urology focus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The gut-kidney microbiome-oxalate axis in calcium oxalate nephrolithiasis: mechanisms and microbiome-based interventions.Frontiers in cellular and infection microbiology · 2026Pooled it
- Lactobacillus acidophilus abolishes oxalate-mediated renal epithelial barrier disruption and calcium oxalate monohydrate crystal adhesion to renal epithelial cells.Cellular & molecular biology letters · 2026Article
- Gut microbiome and metabolome signatures in calcium oxalate stone recurrence: a multi-omics study.Microbial cell factories · 2026Article
- Adherence to the Dietary Index for Gut Microbiota and reduced risk of nephrolithiasis: a case-control study of Chinese adults.Frontiers in nutrition · 2026Article
- Article
- The gut-kidney axis in urolithiasis: roles of gut microbiota, metabolites, and therapeutic implications.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Nephrolithiasis imposes a significant health care burden around the world. In the past decade, there has been considerable interest in the human microbiota in relation to the onset of nephrolithiasis. Most of the research has focused on degradation of oxalate, a known causative factor for nephrolithiasis, by bacteria in the gut. More recently, the role of antibiotic exposure and changes to short-chain fatty acids have been investigated. Studies have revealed that the urinary tract, previously thought to be sterile, harbors resident microbial communities closely associated with nephrolithiasis. In this mini-review, we evaluate potential causative roles of the microbiome in the onset of nephrolithiasis and the development of novel therapies to prevent this disease. PATIENT SUMMARY: This mini-review discusses scientific evidence on the influence of bacteria in our intestines and urinary tract on the formation of kidney stones. We discuss possible therapies targeting these bacteria that could prevent kidney stones from forming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.